Philip Kantoff: RayzeBio brought a new therapy to the clinic to benefit patients with neuroendocrine tumors

Philip Kantoff, Co-Founder and Chief Executive Officer at Convergent Therapeutics, shared on LinkedIn:

“Congratulations to my son Aaron Kantoff, who co-founded RayzeBio, which brought a new therapy to the clinic to benefit patients with neuroendocrine tumors and after a little over 3 years RayzeBio was sold to BMS for 4.1b.”